Regeneron Pharmaceuticals Inc. will offer a gene therapy that restored hearing for a small number of profoundly deaf children ...

Regeneron hauled in $3.6 billion during the first quarter of 2026, as analysts homed in on a slight Eylea HD miss and key ...

The agency's decision is based on results from a clinical trial in which the treatment improved hearing in 80 percent of the ...

Regeneron Pharmaceuticals posted first-quarter revenue and profit above Wall Street expectations, driven by strong sales of Dupixent and Libtayo despite pressure on Eylea. The company also announced a ...

The FDA approved Regeneron's Otarmeni on April 23, making it the first gene therapy for inherited hearing loss — and ...

Regeneron will make its newly approved gene therapy available for free in the U.S. The company hasn't yet decided how much it ...

Regeneron is the latest in a string of major drugmakers to make pricing concessions for new and existing medicines under ...

Otarmeni, now cleared to treat a rare, inherited kind of hearing loss, is the first gene therapy cleared under the FDA’s ...

Sanofi and Novartis kick off the heart of earnings season; Lilly strikes its fourth pact in as many weeks; Regeneron earns ...

Travis Smith was a very serious baby. Born completely unable to hear, his mother, Sierra, struggled to see his personality ...

Kiniksa Pharma (KNSA) stock hit a 52-week high as the company reported better-than-expected Q1 2026 thanks to Regeneron (REGN ...